Additional file 1 of Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma
Creators: name: Wang, Hao-Yuan
name: Yang, Fu-Chen
name: Yang, Ching-Fen
name: Liu, Yao-Chung
name: Ko, Po-Shen
name: Li, Chien-Jung
name: Tsai, Chun-Kuang
name: Chung, Yi-Lin
name: Chen, Nien-Jung
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Cell Biology
subject: Immunology
subject: FOS: Clinical medicine
subject: 19999 Mathematical Sciences not elsewhere classified
subject: FOS: Mathematics
subject: Cancer
subject: Hematology

description: Additional file 1: Additional Figures, Figures S1–S6 Figure S1. Healthy donors. Histogram of (A) surface-TREM2 level on M-MDSCs and (B) intracellular ARG1 level within M-MDSCs; red line denoting the healthy control for flow-cytometry analysis of surface TREM2 and intracellular ARG1. The mRNA transcriptional level of (C) TREM2 and (D) ARG1 being calculated using ΔCT. The absolute counts of (E) CD4+ T cells and (F) CD8+ T cells in PB. ΔCT, delta cycle threshold; ARG1, arginase 1; F, female; M, male; M-MDSCs, monocytic myeloid-derived suppressor cells; mRNA, messenger ribonucleic acid; n, number; PB, peripheral blood; TREM2, triggering receptors expressed on myeloid cells 2. Figure S2. Enrollment algorithm for newly diagnosed and treatment-naïve DLBCL patients. CNS, central nervous system; HIV, human immunodeficiency virus. Figure S3. Progression-free and overall survival for all 100 DLBCL patients. DLBCL, diffuse large B-cell lymphoma; n, number; OS, overall survival; PFS, progression-free survival. Figure S4. Outcomes by treatment-related factors. Progression-free and overall survival being subcategorized by frontline treatment (A, B), induction regimen (C, D), or treatment response after frontline treatment (E, F); P as the log-rank test for Kaplan–Meier estimate. CR, complete remission; mOS, median overall survival; mPFS, median progression-free survival; n, number; NR, non-reach; PD, progressive disease; PR, partial remission; SD, stable disease. Figure S5. Prognostic factors of DLBCL patients. Progression-free and overall survival being subcategorized by (A, B) age, (C, D) sex, (E, F) IPI-risk score, (G, H) bulky mass, (I, J) bone marrow involvement, (K, L) cell of origin, (M, N) double-expressor lymphoma, (O, P) absolute count of CD4+ T cells in PB, or (Q, R) absolute count of CD8+ T cells in PB; the cut-off values of age, absolute counts of CD4+ T cells and CD8+ T cells in PB determined by their medians; P as the log-rank test for Kaplan–Meier estimate. DEL, double-expressor lymphoma; GCB, germinal center B cell; IPI, international prognostic index; mOS, median overall survival; mPFS, median progression-free survival; n, number; NR, non-reach; PB, peripheral blood. Figure S6. Subgroup analysis of hazard ratios for (A) progression-free and (B) overall survival. BM, bone marrow; CI, confidence interval; GCB, germinal center B cell; HR, hazard ratio; IPI, international prognostic index; M-MDSCs, monocytic myeloid-derived suppressor cells; MFI, mean fluorescence intensity; OS, overall survival; PB, peripheral blood; PFS, progression-free survival; Pt. no., patient number; TREM2, triggering receptors expressed on myeloid cells 2.